Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

to respond to a concessor of information diffess it displays a valid of the control number.					
Confirmation Number	9839				
Application Number	10/599497				
Filing Date	September 29, 2006				
First Named Inventor	P.J.L. Quaedflieg et al				
Group Art Unit	1625				
Examiner Name	N.S. Chandrakumar				
Attomey Docket Number	TIP0060USPCT				

**U.S. PATENT DOCUMENTS** 

		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No. <sup>1</sup>		d Code <sup>2</sup> known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		US6127372A		Tung et al.	10/3/2000	

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup> Kind0	Code <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	<b>T</b> <sup>6</sup>
		EP	715618	B1	G.D. SEARLE & CO.   THE MONSANTO COMPANY	6/12/1996		
		wo	2003022853	<b>B</b> 1	TIBOTEC PHARMACEUTICALS LTD.	3/20/2003		
		wo	1995024385	A1	VERTEX PHARMACEUTICALS INCORPORATED	9/14/1995		
		wo	1999065870	A2	VERTEX PHARMACEUTICALS INCORPORATED	12/23/1999		
		wo	1999065870	А3	VERTEX PHARMACEUTICALS INCORPORATED	3/15/2001		
		wo	2000047551	A2	VERTEX PHARMACEUTICALS INCORPORATED	8/17/2000		
		wo	2000047551	A3	VERTEX PHARMACEUTICALS INCORPORATED	8/16/2001		
		wo	2000076961	A1	VERTEX PHARMACEUTICALS INCORPORATED	12/21/2000		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

dito respond to a conection of finormation diffess it displays a valid OND control number.					
Confirmation Number	9839				
Application Number	10/599497				
Filing Date	September 29, 2006				
First Named Inventor	P.J.L. Quaedflieg et al				
Group Art Unit	1625				
Examiner Name	N.S. Chandrakumar				
Attorney Docket Number	TIP0060USPCT				

#### U.S. PATENT DOCUMENTS

		U.S. Patent Do	ocument		Data of Dublication	Danca Calumna Linea
Examiner Initials	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear

### FOREIGN PATENT DOCUMENTS

		Foreign	Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where	
Examiner Cite Initials No.		Office <sup>3</sup>	Number <sup>4</sup> KindCod	e <sup>5</sup>	Applicant of Cited Document	Cited Document mm-dd-yyyy	relevant passages or relevant figures appear	T <sup>6</sup>
		wo	2001025240	A1	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; NATIONAL INSTITUTES OF HEALTH	4/12/2001		
		wo	1999067417	A2	THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	12/29/1999		
		wo	1999067417	A3	None	9/28/2000		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

possible. s Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

to respond to a concentral when hater unless it displays a valid of the control hamber.					
Confirmation Number	9839				
Application Number	10/599497				
Filing Date	September 29, 2006				
First Named Inventor	P.J.L. Quaedflieg et al				
Group Art Unit	1625				
Examiner Name	N.S. Chandrakumar				
Attomey Docket Number	TIP0060USPCT				

Examiner's nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Ghosh, et al "Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R-	
		Hydroxyethylamino) Sulfonamide Isostere''', Bioorganic & Medicinal Chemistry Letters , Oxford	
4		GB, Volume 8, No. 6, March 17, (1998) pp. 687-690.	
		Ghosh et al., "Nonpeptidal P2 Ligands for HIV protease Inhibitors; Structure Based Design,	
		Synthesis, and Biological Evaluation "J. Med. Chem. (1996) Volume 39, pp. 3278-3290	
		Pezeck et al., "A New Route to Perhydro and Tetrahydro Furo-2, 3b Furans Via Radical	
		Cyclisation", Tetrahedron Letters, (1986) Volume 27, No. 32, pp. 3715-3718	
		Uchiyama et al., "Stereoselevtive synthesis of optically active perhydrofurol [2,3-b] furan	
		derivatives", Tetrahedron Letters, (2001), Vol. 42, pp. 4653-4656	
		C. Hubschwerlen, "A convenient Syntesis of L-(s) Glyceraldehyde Acetonide form L-Ascorbiic	
		Acid", Synthesis (1986) pp. 962-964	
		C.R. Schmid et al., "Synthesis of 2,3 O Isopropylidene glyceraldehyde High Chemical and	
		Optical Purity: Observation on the Development of a Practical Bulk Process", J. Org. Chem.	
		(1991), Volume 56, pp. 4056-4058	
		Krief et al., "Diastereoselective Synthesis of Dimethyl Cycloropane-1, 1-Dicarboxylates from	
		a y-Alkosy Alkylidene Malonate and Sulfer and Phosphorus Ylides", Tetrahedron Lett. 1998,	
		39, 1437-1440	
		N. Kornblum "The Synthesis of Aliphatic and Nitro Compounds", Organic reactions, (1962),	
		Volume 12, 101	
		H.W. Pinnick, Organic Reactions (1990), Vol. 38, pp. 655-792	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450